6-(3-chloro-4-morpholino-phenyl)-5-hydroxymethyl-4,5-dihydro-2H-pyridazine-3-one | 102625-16-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 6-(3-chloro-4-morpholino-phenyl)-5-hydroxymethyl-4,5-dihydro-2H-pyridazine-3-one
• 英文别名: 6-(3-chloro-4-morpholino-phenyl)-5-hydroxymethyl-4,5-dihydro-3(2H)-pyridazinone；3-(3-chloro-4-morpholin-4-ylphenyl)-4-(hydroxymethyl)-4,5-dihydro-1H-pyridazin-6-one
• CAS: 102625-16-1
• 化学式: C₁₅H₁₈ClN₃O₃
• 分子量: 323.779
• InChiKey: VGDQUUGAZDJCEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  74.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(3-chloro-4-morpholino-benzoyl)-4-hydroxybutyric acid morpholine amide 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以30%的产率得到6-(3-chloro-4-morpholino-phenyl)-5-hydroxymethyl-4,5-dihydro-2H-pyridazine-3-one
  参考文献：
  名称：

  6-(4-Morpholino-phenyl)-4,5-dihydro-2H-pyridazine-3-ones: potent platelet aggregation inhibitors and antithrombotics

  摘要：

  A series of di- and tri-substituted 6-phenyl-4,5-dihydro-2H-pyridazine-3-ones is described. The compounds were designed to be antithrombotics and were assessed for their inhibitory properties on platelet aggregation and on thrombus formation in an arteriovenous shunt in the rat. The synthesis and physical properties of the compounds are described. The structure-activity relationships reveal that non-aromatic nitrogen-containing heterocycles can confer high activity on the 6-phenyl-pyridazinone system, provided they are combined with an additional electron-withdrawing substituent in the phenyl ring. The most potent compounds (8i, 8b) had an ED(min) of 1-3 mg/kg after oral administration in the thrombus formation test.

  DOI：

  10.1016/0223-5234(91)90121-3

文献信息

• Substituted pyridazinones, pharmaceutical preparations containing these
  申请人：Ciba-Geigy Corporation

  公开号：US04624951A1

  公开（公告）日：1986-11-25

  The present invention relates to novel substituted pyridazinones of the general formula I ##STR1## wherein R is a halogen atom, a lower alkyl or lower alkoxy group, the nitro, hydroxyl, cyano, carboxyl, lower alkoxycarbonyl or carbamoyl group or the trifluoromethyl group, and Z is hydrogen or an acyl group, and the salts and tautomeric forms thereof, which have a marked antithrombotic action, to the production of these novel compounds, to pharmaceutical preparations containing them, and to their use.

  本发明涉及一种新型取代吡啶并咪唑酮，其一般式为I：##STR1## 其中R为卤素原子、低烷基或低烷氧基、硝基、羟基、氰基、羧基、低烷氧基羰基或氨基甲酰基，或三氟甲基基团，Z为氢原子或酰基团，以及其盐和互变异构体，具有显著的抗血栓作用，本发明还涉及这些新化合物的制备、含有它们的药物制剂以及它们的使用。
• Substituierte Pyridazinone, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen und deren Verwendung
  申请人：CIBA-GEIGY AG

  公开号：EP0172141A1

  公开（公告）日：1986-02-19

  Die vorliegende Erfindung betrifft neue substituierte Pyridazinone der allgemeinen Formel I worin R ein Halogenatom, eine Niederalkyl-, Niederalkoxy-, die Nitro-, Hydroxy-, Cyano-, Carboxy-, Niederalkoxycarbonyl-, Carbamoyl- oder die Trifluormethylgruppe bedeutet, und Z Wasserstoff oder eine Acylgruppe bedeutet, ihre Salze und ihre tautomeren Formen mit ausgeprägter antithrombotischer Wirksamkeit, deren Herstellung, sowie pharmazeutische Präparate, die diese neuen Verbindungen enthalten, und auch ihre Verwendung.

  本发明涉及通式 I 的新型取代哒嗪酮类化合物 其中 R 代表卤素原子、低级烷基、低级烷氧基、硝基、羟基、氰基、羧基、低级烷氧羰基、氨基甲酰基或三氟甲基，Z 代表氢或酰基、它们的盐及其具有明显抗血栓活性的同分异构形式、它们的制备方法以及含有这些新化合物的药物组合物，以及它们的用途。
• US4624951A
  申请人：——

  公开号：US4624951A

  公开（公告）日：1986-11-25
• 6-(4-Morpholino-phenyl)-4,5-dihydro-2H-pyridazine-3-ones: potent platelet aggregation inhibitors and antithrombotics
  作者：R Goeschke、J Gainer、GA Howarth、RB Wallis、R Kerry、J Ambler、VS Findlay、KD Butler

  DOI：10.1016/0223-5234(91)90121-3

  日期：1991.10

  A series of di- and tri-substituted 6-phenyl-4,5-dihydro-2H-pyridazine-3-ones is described. The compounds were designed to be antithrombotics and were assessed for their inhibitory properties on platelet aggregation and on thrombus formation in an arteriovenous shunt in the rat. The synthesis and physical properties of the compounds are described. The structure-activity relationships reveal that non-aromatic nitrogen-containing heterocycles can confer high activity on the 6-phenyl-pyridazinone system, provided they are combined with an additional electron-withdrawing substituent in the phenyl ring. The most potent compounds (8i, 8b) had an ED(min) of 1-3 mg/kg after oral administration in the thrombus formation test.